Alvotech (ALVO) said late Monday it has commenced an underwritten public offering of its ordinary shares and a concurrent private placement that are expected to generate about $125 million in gross proceeds.

The company said it expects to grant the underwriters a 30-day option to buy up to an additional 15% of the ordinary shares sold in the public offering at the public offering price, less underwriting discounts and commissions.

Alongside the offering, Alvotech expects to enter into subscription agreements with certain investors in the European Economic Area under which it will issue and sell ordinary shares at the public offering price in a private placement, according to the statement.

The consummation of the offering is not contingent on the consummation of the concurrent private placement, the company said.

Alvotech plans to use net proceeds from the offering and the private placement to fund the continued development of its biosimilar assets, as well as working capital and general corporate purposes.